SEARCH

SEARCH BY CITATION

References

  • 1
    Giordano M, Matsuda M, Sanders L, et al. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes. 1995;44:665671.
  • 2
    Glanz M, Garber AJ, Mancia G, et al. Meta-analysis of studies using selective alpha 1-blockers in patients with hypertension and type 2 diabetes. Int J Clin Pract. 2001;55:694701.
  • 3
    Julius S. Are different hemodynamic patterns of antihypertensive drugs clinically important? Eur J Clin Pharmacol. 1990;38:S125S128.
  • 4
    Grimm RA Jr, Flack JM, Schoenberger JA, et al. Alpha-blockade and thiazide treatment of hypertension. A double-blind randomized trial comparing doxazosin and hydrochlorothiazide. Am J Hypertens. 1996;9:445454.
  • 5
    Maheux P, Facchini F, Jeppesen J, et al. Changes in glucose, insulin, lipid, lipoprotein, and apoprotein concentrations and insulin action in doxazosin-treated patients with hypertension. Comparison between nondiabetic individuals and patients with non-insulin-dependent diabetes mellitus. Am J Hypertens. 1994;7:416424.
  • 6
    Fujimoto WY. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am J Med. 2000;108(suppl 6a):9S14S.
  • 7
    McVeigh GE. Arterial compliance in hypertension and diabetes mellitus. Am J Nephrol. 1996;16:217222.
  • 8
    Verges BL. Dyslipidaemia in diabetes mellitus. Review of the main lipoprotein abnormalities and their consequences on the development of atherogenesis. Diabetes Metab. 1999;25(suppl 3):3240.
  • 9
    Ritz E, Rychlik I, Locatelli F, et al. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis. 1999;34:795808.
  • 10
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283:19671975.
  • 11
    Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension. 2003;42:239246.
  • 12
    Davis BR, Cutler JA, Gordon DJ, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Am J Hypertens. 1996;9:342360.
  • 13
    Barzilay JI, Jones CL, Davis BR, et al. Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care. 2001;24:654658.
  • 14
    Barzilay JI, Spiekerman CF, Kuller LH, et al. Prevalence of clinical and isolated subclinical cardiovascular disease in older adults with glucose disorders: The Cardiovascular Health Study. Diabetes Care. 2001;24:12331239.
  • 15
    Kostis J, Davis BR, Cutler JA, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1997;278:212216.
  • 16
    Davis BR, Cutler JA, Furberg CD, et al. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Ann Intern Med. 2002;137:313320.
  • 17
    Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002:360:19031913.
  • 18
    Riegger GA, Haeske W, Kraus C, et al. Contribution of the renin-angiotensin-aldosterone system to development of tolerance and fluid retention in chronic congestive heart failure during prazosin treatment. Am J Cardiol. 1987;59:906910.
  • 19
    Piller LB, Davis BR, Cutler JA, et al. Validation of heart failure events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants assigned to doxazosin and chlorthalidone. Curr Cont Trials Cardiovasc Med. 2002;3:110.
  • 20
    Barzilay JI, Kronmal RA, Gottdiener JS, et al. The association of fasting glucose levels with congestive heart failure in diabetic adults, ≥65 years: the Cardiovascular Health Study. J Am Coll Cardiol. In press.